<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046652</url>
  </required_header>
  <id_info>
    <org_study_id>0408087106</org_study_id>
    <nct_id>NCT05046652</nct_id>
  </id_info>
  <brief_title>Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series</brief_title>
  <official_title>Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maranatha Christian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Primaya Hospital Tangerang Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maranatha Christian University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first Case Studies article highlight factors determine the effectiveness of&#xD;
      Convalescent Plasma Therapy (CPT) in Indonesia, accompanied by supporting data and images&#xD;
      before and after the patients received the therapy. This Case Studies gives a huge&#xD;
      contribution as CPT still on going as multicentre study and apply massively as emergency&#xD;
      approved treatment in Indonesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were&#xD;
      included. Four patients had been administered two doses of 200 mL convalescent plasma (CP)&#xD;
      and another four patients had been administered one dose of CP with an antibody titer of&#xD;
      1:320. This study has three goals included to detect the improvement of patient clinical and&#xD;
      laboratory conditions, safety of CPT, and conversion from positive to negative results after&#xD;
      CPT administration. Convalescent plasma applied within two weeks (13 days) from onset of&#xD;
      illness and within a week (6.5 days) from the first day of hospital admission for all&#xD;
      patients. Improvements in clinical symptoms, laboratory parameters, thorax photo, negative&#xD;
      conversion of PCR, and decreased oxygen supplementation occurred within a week after CPT.&#xD;
      Patients with two doses of CP tended to have faster recovery than those with one dose of CP.&#xD;
      No severe adverse effects were observed in any patient. This is the first case series in&#xD;
      Indonesia showing CPT is safe and well tolerated, and early CPT before the patient is&#xD;
      intubated could potentially prevent disease progression, increase the recovery rate, and&#xD;
      shorten the inpatient days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients with two doses of CP tended to have faster recovery than those with one dose of CP.</measure>
    <time_frame>1 April 2020 - 31 December 2020</time_frame>
    <description>The median time from onset of illness to CPT was 13 days (within two weeks), and from the first day of hospital admission to CPT was 6.5 days (within a week). There were improvements in clinical symptoms, laboratory parameters, thorax photo, negative conversion of PCR, and decreased oxygen supplementation within a week after CPT. No severe adverse effects were observed in any patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients with two doses of CP tended to have faster PCR negative conversion time than those with one dose of CP</measure>
    <time_frame>1 April 2020 - 31 December 2020</time_frame>
    <description>All four patients given two doses of CP became negative in PCR swab but only two of four patients given one dose of CPT showed negative PCR swab result</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Infectious Disease</condition>
  <arm_group>
    <arm_group_label>One bag of convalescent plasma therapy</arm_group_label>
    <description>Four patients had been administered one dose of 200 mL CP with an antibody titer of 1:320.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two bags of convalescent plasma therapy</arm_group_label>
    <description>Four patients had been administered two doses of 200 mL CP with an antibody titer of 1:320.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent Plasma Therapy</intervention_name>
    <description>In this study, eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320.</description>
    <arm_group_label>One bag of convalescent plasma therapy</arm_group_label>
    <arm_group_label>Two bags of convalescent plasma therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eight patients originated from one region of Tangerang with positive PCR swab&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COVID-19 patients&#xD;
&#xD;
          -  Severe stage&#xD;
&#xD;
          -  Positive PCR swab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-COVID-19 patients&#xD;
&#xD;
          -  No Symptoms COVID-19 patients&#xD;
&#xD;
          -  Mild COVID-19 patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresia M Rahardjo, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maranatha Christian University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Theresia Monica Monica</name>
      <address>
        <city>Bandung</city>
        <state>West Java</state>
        <zip>40164</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Indonesia: WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard</citation>
  </reference>
  <reference>
    <citation>Ozdemir OHE. Convalescent (Immune) Plasma Therapy with all Aspects: Yesterday, Today and COVID-19. Erciyes Med J. 2020;1-8.</citation>
  </reference>
  <reference>
    <citation>Rahardjo TM, Triyono T, Harly PR. Buku Penatalaksanaan Terapi Plasma Konvalesen Bagi Pasien COVID-19 Di Indonesia. Revised Edition. September 2020.</citation>
  </reference>
  <results_reference>
    <citation>Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.</citation>
    <PMID>32167489</PMID>
  </results_reference>
  <results_reference>
    <citation>Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent Plasma Therapy for COVID-19: State of the Art. Clin Microbiol Rev. 2020 Aug 12;33(4). pii: e00072-20. doi: 10.1128/CMR.00072-20. Print 2020 Sep 16. Review.</citation>
    <PMID>32792417</PMID>
  </results_reference>
  <results_reference>
    <citation>Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, van Buskirk C, Grossman BJ, Joyner M, Henderson JP, Pekosz A, Lau B, Wesolowski A, Katz L, Shan H, Auwaerter PG, Thomas D, Sullivan DJ, Paneth N, Gehrie E, Spitalnik S, Hod EA, Pollack L, Nicholson WT, Pirofski LA, Bailey JA, Tobian AA. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020 Jun 1;130(6):2757-2765. doi: 10.1172/JCI138745. Review.</citation>
    <PMID>32254064</PMID>
  </results_reference>
  <results_reference>
    <citation>Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496. doi: 10.1073/pnas.2004168117. Epub 2020 Apr 6.</citation>
    <PMID>32253318</PMID>
  </results_reference>
  <results_reference>
    <citation>Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.</citation>
    <PMID>32219428</PMID>
  </results_reference>
  <results_reference>
    <citation>Abolghasemi H, Eshghi P, Cheraghali AM, Imani Fooladi AA, Bolouki Moghaddam F, Imanizadeh S, Moeini Maleki M, Ranjkesh M, Rezapour M, Bahramifar A, Einollahi B, Hosseini MJ, Jafari NJ, Nikpouraghdam M, Sadri N, Tazik M, Sali S, Okati S, Askari E, Tabarsi P, Aslani J, Sharifipour E, Jarahzadeh MH, Khodakarim N, Salesi M, Jafari R, Shahverdi S. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfus Apher Sci. 2020 Oct;59(5):102875. doi: 10.1016/j.transci.2020.102875. Epub 2020 Jul 15.</citation>
    <PMID>32694043</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, Sanky C, Dupper A, Zheng A, Nguyen FT, Amanat F, Stadlbauer D, Altman DR, Chen BK, Krammer F, Mendu DR, Firpo-Betancourt A, Levin MA, Bagiella E, Casadevall A, Cordon-Cardo C, Jhang JS, Arinsburg SA, Reich DL, Aberg JA, Bouvier NM. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020 Nov;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15.</citation>
    <PMID>32934372</PMID>
  </results_reference>
  <results_reference>
    <citation>Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, Esteban I, Caballero MT, Wood C, Berrueta M, Rondan A, Lescano G, Cruz P, Ritou Y, Fernández Viña V, Álvarez Paggi D, Esperante S, Ferreti A, Ofman G, Ciganda Á, Rodriguez R, Lantos J, Valentini R, Itcovici N, Hintze A, Oyarvide ML, Etchegaray C, Neira A, Name I, Alfonso J, López Castelo R, Caruso G, Rapelius S, Alvez F, Etchenique F, Dimase F, Alvarez D, Aranda SS, Sánchez Yanotti C, De Luca J, Jares Baglivo S, Laudanno S, Nowogrodzki F, Larrea R, Silveyra M, Leberzstein G, Debonis A, Molinos J, González M, Perez E, Kreplak N, Pastor Argüello S, Gibbons L, Althabe F, Bergel E, Polack FP; Fundación INFANT-COVID-19 Group. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.</citation>
    <PMID>33406353</PMID>
  </results_reference>
  <results_reference>
    <citation>Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6.</citation>
    <PMID>15616839</PMID>
  </results_reference>
  <results_reference>
    <citation>Sun M, Xu Y, He H, Zhang L, Wang X, Qiu Q, Sun C, Guo Y, Qiu S, Ma K. A potentially effective treatment for COVID-19: A systematic review and meta-analysis of convalescent plasma therapy in treating severe infectious disease. Int J Infect Dis. 2020 Sep;98:334-346. doi: 10.1016/j.ijid.2020.06.107. Epub 2020 Jul 4.</citation>
    <PMID>32634589</PMID>
  </results_reference>
  <results_reference>
    <citation>Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007 Sep 13;357(11):1162-3.</citation>
    <PMID>17855683</PMID>
  </results_reference>
  <results_reference>
    <citation>Aviani JK, Halim D, Soeroto AY, Achmad TH, Djuwantono T. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics. Rev Med Virol. 2021 Feb 23. doi: 10.1002/rmv.2225. [Epub ahead of print] Review.</citation>
    <PMID>33621405</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maranatha Christian University</investigator_affiliation>
    <investigator_full_name>Theresia Monica Rahardjo</investigator_full_name>
    <investigator_title>Director of Unggul Karsa Medika Hospital</investigator_title>
  </responsible_party>
  <keyword>convalescent plasma therapy</keyword>
  <keyword>non-intubated</keyword>
  <keyword>case studies</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

